TRSO's Revenue Jumps Amidst Soaring Losses and Aggressive AI Acquisitions

TL;DR

**TRSO is burning cash at an alarming rate to fuel an acquisition spree, making it a high-risk, high-reward bet on future AI dominance.**

AI Summary

TRANSUITE.ORG INC. (TRSO) reported a significant increase in revenue to $115,000 for the nine months ended September 30, 2025, compared to $0 in the prior year, driven by strategic acquisitions. However, the company experienced a substantial net loss of $27,965,403 for the nine months ended September 30, 2025, a dramatic increase from a net loss of $285,672 in the same period of 2024. This increased loss is primarily due to a surge in professional fees, including $27,938,890 in stock-based compensation. TRSO's total assets grew exponentially to $37,408,838 at September 30, 2025, from $71,634 at December 31, 2024, largely due to the acquisition of goodwill and intangible assets totaling over $37 million from entities like SolanAI Global Ltd. and Xirangsheng (Shenzhen) Health Technology Co., Ltd. The company's accumulated deficit also widened to $28,429,710. TRSO is actively pursuing revenue growth, strategic expansion through acquisitions, market development, and technology advancement, but faces a going concern risk due to its accumulated deficit and negative operating cash flow.

Why It Matters

TRSO's aggressive acquisition strategy, particularly in AI and Web3, signals a bold move to establish market leadership, but the massive increase in net loss and accumulated deficit raises serious questions about financial sustainability for investors. The significant stock-based compensation for professional fees could dilute existing shareholders and impact future profitability. For employees and customers, these acquisitions could mean expanded product offerings and a more robust AI ecosystem, potentially intensifying competition in the AI workforce as a service (AWaaS) sector. The company's ability to integrate these acquisitions and achieve profitability will dictate its long-term viability and impact on the broader AI market.

Risk Assessment

Risk Level: high — TRSO reported an accumulated deficit of $28,429,710 and negative operating cash flow of $28,209 for the nine months ended September 30, 2025, indicating significant financial instability. The company's ability to continue as a going concern is contingent on securing future financing, which is not assured, as explicitly stated in Note 2. The substantial increase in professional fees, including $27,938,890 in stock-based compensation, further exacerbates cash burn and shareholder dilution concerns.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence on TRSO. Given the high accumulated deficit and negative operating cash flow, consider this a highly speculative investment. Monitor closely for successful integration of recent acquisitions and concrete evidence of revenue growth translating into reduced net losses and positive cash flow before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$115,000

operating Margin

N/A

total Assets

$37,408,838

total Debt

N/A

net Income

-$27,965,403

eps

-$0.96

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $115,000 — Revenues (for the nine months ended September 30, 2025, up from $0 in 2024)
• $27,965,403 — Net Loss (for the nine months ended September 30, 2025, significantly higher than $285,672 in 2024)
• $27,938,890 — Stock-based compensation (included in professional fees for the nine months ended September 30, 2025)
• $37,408,838 — Total Assets (as of September 30, 2025, a substantial increase from $71,634 at December 31, 2024)
• $28,429,710 — Accumulated Deficit (as of September 30, 2025, widened from $458,919 at December 31, 2024)
• $12,500,000 — Fair value of SolanAI Global Ltd. acquisition (initial consideration for 51% equity interest)
• $1,700,000 — Fair value of Xirangsheng (Shenzhen) Health Technology Co., Ltd. acquisition (initial consideration for 100% equity interest)
• $28,209 — Negative Operating Cash Flow (for the nine months ended September 30, 2025)
• 47,869,093 — Shares of Common Stock outstanding (as of September 30, 2025, up from 4,046,760 at December 31, 2024)
• $0.96 — Net Loss Per Common Share – Basic and Diluted (for the three months ended September 30, 2025, compared to $0.05 in 2024)

Key Players & Entities

• TRANSUITE.ORG INC. (company) — registrant and AI solutions provider
• Goldfinch Group Holdings Ltd. (company) — 70% controlled subsidiary, later wholly owned
• SolanAI Global Ltd. (company) — 51% acquired Hong Kong AI technology company
• Xirangsheng (Shenzhen) Health Technology Co., Ltd. (company) — 100% acquired AI Social Agent and Traditional Chinese Medicine enterprise
• Fidelity World Holdings Ltd. (company) — seller of 30% equity in Goldfinch Group Holdings Ltd.
• Crestar Holdings Ltd. (company) — wholly owned subsidiary of Goldfinch Group Holdings Ltd.
• Hailiang Li (person) — seller in SolanAI Global Ltd. and Xirangsheng (Shenzhen) Health Technology Co., Ltd. acquisitions
• Fujian Wochong Intelligent Technology Co., Ltd. (company) — potential acquisition target (51% equity interest)
• SYD GOLDX PTY LTD (company) — potential acquisition target (51% equity interest in Australian licensed Digital Currency Exchange)
• Tsinghua University (company) — origin of TRSO's leadership team

FAQ

Risk Factors

• Going Concern Risk [high — financial]: The company faces a going concern risk due to a significant accumulated deficit of $28,429,710 as of September 30, 2025, and negative operating cash flow of $28,209 for the nine months ended September 30, 2025. This indicates a substantial and ongoing need for capital to sustain operations.
• Stock-Based Compensation Expense [high — financial]: A substantial portion of the net loss, $27,938,890 out of $27,965,403, for the nine months ended September 30, 2025, is attributable to stock-based compensation. This highlights a significant non-cash expense that heavily impacts profitability and dilutes existing shareholders.
• Integration of Acquired Entities [medium — operational]: The company's rapid growth is heavily reliant on strategic acquisitions, including SolanAI Global Ltd. and Xirangsheng (Shenzhen) Health Technology Co., Ltd. The successful integration of these entities and the realization of their projected value are critical operational risks.
• Asset Valuation and Goodwill [medium — financial]: Total assets increased dramatically to $37,408,838 from $71,634, largely due to over $37 million in goodwill and intangible assets from acquisitions. The valuation and potential impairment of these intangible assets represent a significant financial risk.
• Dilution from Share Issuances [high — financial]: The number of outstanding shares increased from 4,046,760 at December 31, 2024, to 47,869,093 at September 30, 2025. This substantial increase, likely related to acquisitions and compensation, poses a significant dilution risk for existing shareholders.

Industry Context

The software and technology sector, particularly companies focused on AI and health technology, is characterized by rapid innovation and significant M&A activity. Companies often rely on acquisitions to gain market share, acquire technology, and achieve scale. However, this also leads to high valuations for acquired assets and potential integration challenges.

Regulatory Implications

As a publicly traded company, TRSO is subject to SEC regulations, including timely and accurate financial reporting. The significant stock-based compensation and the potential for goodwill impairment could attract scrutiny from auditors and regulators regarding valuation and accounting practices.

What Investors Should Do

1. Monitor acquisition integration and performance
2. Analyze the sustainability of stock-based compensation
3. Evaluate cash burn and funding needs
4. Assess the going concern risk

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reporting period showing significant revenue increase but a substantial net loss, driven by acquisitions and stock-based compensation.
• 2025-09-30: Total Assets as of September 30, 2025 — Marked a substantial increase to $37,408,838, primarily due to goodwill and intangible assets from acquisitions.
• 2025-09-30: Accumulated Deficit as of September 30, 2025 — Widened to $28,429,710, highlighting ongoing unprofitability.
• 2024-12-31: Total Assets as of December 31, 2024 — Baseline figure of $71,634, against which the significant asset growth in 2025 is measured.
• 2024-12-31: Accumulated Deficit as of December 31, 2024 — Baseline figure of $458,919, showing the increase in cumulative losses.
• 2024-09-30: Nine months ended September 30, 2024 — Prior period comparison showing $0 revenue and a net loss of $285,672.

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (A significant component of TRSO's asset growth, arising from acquisitions, which carries a risk of impairment if the acquired business underperforms.)

Intangible Assets

Non-physical assets that have value, such as patents, copyrights, trademarks, and brand recognition. In this context, it also includes assets from acquisitions. (Contributes significantly to TRSO's asset base post-acquisition, with valuation and potential impairment being key considerations.)

Stock-based compensation

Compensation provided to employees or executives in the form of stock options or shares, rather than cash. (A major driver of TRSO's net loss for the period, representing a significant non-cash expense impacting profitability.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (TRSO has a substantial and growing accumulated deficit, indicating a history of unprofitability and raising going concern issues.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (TRSO's financial condition, including its accumulated deficit and negative cash flow, raises substantial doubt about its ability to continue as a going concern.)

Operating Cash Flow

The cash generated from a company's normal business operations. (TRSO reported negative operating cash flow, indicating that its core business operations are consuming cash rather than generating it.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, TRANSUITE.ORG INC. (TRSO) has shifted from zero revenue to $115,000, a positive top-line development driven by acquisitions. However, this growth is overshadowed by a dramatic increase in net loss, from $285,672 to $27,965,403, largely due to a surge in stock-based compensation. Total assets have exploded from $71,634 to $37,408,838, reflecting the significant goodwill and intangible assets from recent acquisitions, while the accumulated deficit has also widened considerably, exacerbating the going concern risk.

Key Financial Figures

• $20,878,790 — (including stock-based compensation of $20,878,790 and $0 for three months ended September
• $0 — k-based compensation of $20,878,790 and $0 for three months ended September 30, 20
• $27,938,890 — s ended September 30, 2025 and 2024 and $27,938,890 and $0 for nine months ended September
• $12,501,149 — As of September 30, 2025, goodwill of $12,501,149 was generated through the acquisition o

Filing Documents

• trso_10q.htm (10-Q) — 677KB
• trso_ex311.htm (EX-31.1) — 25KB
• trso_ex321.htm (EX-32.1) — 10KB
• 0001640334-25-002157.txt ( ) — 3319KB
• trso-20250930.xsd (EX-101.SCH) — 38KB
• trso-20250930_lab.xml (EX-101.LAB) — 227KB
• trso-20250930_cal.xml (EX-101.CAL) — 38KB
• trso-20250930_pre.xml (EX-101.PRE) — 190KB
• trso-20250930_def.xml (EX-101.DEF) — 106KB
• trso_10q_htm.xml (XML) — 354KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 20

SIGNATURES

SIGNATURES 21 2 Table of Contents Transuite.Org Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2025 2024 (Unaudited) (Audited) ASSETS Current Assets Cash and cash equivalents $ 14,030 $ - Fund held in trust - 16,103 Accounts receivable 15,000 - Other receivable and prepayment 16,062 - Due from related party - 15,000 Deferred share issuance cost 254,750 - Total Current Assets $ 299,842 $ 31,103 Other Assets Goodwill 12,501,149 - Intangible assets, net 24,607,847 40,531 Total Assets $ 37,408,838 $ 71,634 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued liabilities $ 85,353 $ 66,367 Accrued interest 14,477 3,253 Due to related party 3,212 2,154 Convertible note - 153,520 Stock payable 50,000 - Total Current Liabilities 153,042 225,294 Loan payable 172,062 148,442 Contingent liability 22,875,281 - Total Liabilities 23,200,385 373,736 Commitments and Contingencies (Note 12) STOCKHOLDERS' EQUITY (DEFICIT) Common Stock: $ 0.001 par value, 75,000,000 shares authorized, 47,869,093 shares and 4,046,760 shares issued and outstanding, respectively 47,869 4,047 Additional paid-in capital 42,592,082 143,843 Accumulated deficit ( 28,429,710 ) ( 458,919 ) Total equity (deficit) attributed to Transuite.Org. Inc. 14,210,241 ( 311,029 ) Non-controlling interest ( 1,788 ) 8,927 Total Stockholders' Equity (Deficit) 14,208,453 ( 302,102 ) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 37,408,838 $ 71,634 The accompanying notes are an integral part of the condensed consolidated financial statements. Transuite.Org Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Revenues $ 65,000 $ - $ 115,000 $ - Operating Expenses G

View Full Filing

View this 10-Q filing on SEC EDGAR